Colorectal Cancer
Conditions
Keywords
Curcumin, Colorectal Cancer, GWAS
Brief summary
Colorectal cancer is a major problem in the United States and other developed countries. A safe and effective chemopreventive agent could reduce the burden of colorectal neoplasia. Curcumin, is a product that is derived from Curcuma longa. It has been used for thousands of years as a traditional remedy. Curcumin blocks a number of targets involved in tumor initiation, promotion, and progression, and is considered a promising chemopreventive agent. The investigators propose to enroll 40 patients after screening colonoscopy who will have rectal biopsies at baseline and after 4 weeks of curcumin 4 grams per day. The investigators will use microarray analysis to identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies. The study will also evaluate tolerability and toxicity.
Interventions
DRUGCurcumin C3 tablet
4 grams Curcumin C3 tablet daily x30 days
Sponsors
University of North Carolina, Chapel Hill
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 40 - 80. 2. A willingness to follow the study protocol, as indicated by provision of informed consent to participate 3. Good general health
Exclusion criteria
1. Familial colorectal cancer syndromes (e.g. Hereditary Non-Polyposis Colon Cancer, Familial Adenomatous Polyposis) 2. Ulcerative colitis or Crohn's disease. 3. History of large bowel resection for any reason 4. Diagnosed narcotic or alcohol dependence 5. Unwillingness to forgo curcumin/turmeric-containing supplements during the trial or consumption of curry/turmeric at meals \> 3 times a week. 6. Allergy to turmeric/curcumin. 7. Women with childbearing potential who do not agree to practice effective birth control. 8. Individuals with creatinine, AST or ALT above 1.5 times the upper limit of normal at baseline. 9. Personal or inherited bleeding disorders or therapeutic anti-coagulation with warfarin. 10. Women who are pregnant or nursing. 11. Individuals who have taken antibiotics within the three months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Apoptosis | 30 days | Immunohistochemistry (IHC) signal as intensity and proportion of cells stained |
| Gene expression | 30 days | Change in gene expression |
| Ribonucleic acid (RNA) level | 30 days | Transcript level as mRNA copies per cell |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events | 30 days |
Countries
United States
Outcome results
None listed